Identify 70 bp repeat-associated chromatin components by End-targeting Proteomics of Isolated Chromatin segments (PICh) and initiate their functional characterization
通过分离染色质片段 (PICh) 的末端靶向蛋白质组学鉴定 70 bp 重复相关染色质成分,并启动其功能表征
基本信息
- 批准号:10417263
- 负责人:
- 金额:$ 7.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-04 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAffectAfricaAfricanAfrican TrypanosomiasisAnimalsBindingBinding ProteinsCell surfaceChromatinComplexConserved SequenceCountryCoupledDNADNA Double Strand BreakDevelopmentDiseaseDrug resistanceEconomic BurdenEventFluorescent in Situ HybridizationFrequenciesFutureGene ConversionGenerationsGenesGenetic RecombinationHumanImmune responseImmunofluorescence ImmunologicImmunologic SurveillanceIn SituInfectionLinkMass Spectrum AnalysisMediatingMessenger RNAParasitesPathogenesisPathway interactionsPharmaceutical PreparationsPlayProteinsProteomicsProtocols documentationPseudogenesRNA InterferenceRNA ProbesRegulationRoleSaharaSequence HomologySiteSurface AntigensTimeTrypanosoma brucei bruceiWorkcell growthcell typederepressiongenetic informationimprovedmortalityside effecttelomere
项目摘要
Project Summary
Trypanosoma brucei causes human African trypanosomiasis, which is frequently fatal without treatment.
Few drugs are available for treating this disease, most of which have severe side-effects and are difficult to
administer, while drug-resistant T. brucei infection has been on the rise. In addition, T. brucei also causes
animal African trypanosomiasis, which has been a significant economic burden in sub-Sahara Africa. It is
therefore important to further study T. brucei pathogenesis and identify better targets for future development of
anti-parasite agents. T. brucei regularly switches its major surface antigen, VSG, to evade its mammalian host
immune response. VSG switching is a major pathogenesis mechanism that enables T. brucei to
establish and maintain a long-term infection. However, how VSG switching is initiated naturally in T.
brucei is still not clear. T. brucei has >2,500 VSG genes and pseudogenes, all of which are located at
subtelomeres. However, VSGs are expressed exclusively from subtelomeric polycistronic VSG expression
sites (ESs). VSG is the last gene in any ES and within 2 kb from the telomere repeats. T. brucei has multiple
ESs with very similar sequences, but only one ES is fully active at any time, resulting in a single type of VSG
being expressed on the cells surface. DNA recombination has been shown to be a major pathway for VSG
switching. Most VSG genes are flanked by two common sequences, which provide sequence homology for
recombination between the active and a silent VSG gene in DNA recombination-mediated VSG switching
events. First, all VSG 3’UTR has a common 14 nt sequences. Long telomere sequences are also found
downstream of ES-linked VSGs and VSGs at minichromosome subtelomeres. Second, upstream of most VSG
genes are 70 bp repeats. The 70 bp repeats in ESs can be several kb to several tens kb long. It has been
shown that introducing a DNA double strand break in the 70 bp repeats immediately upstream of the active
VSG gene increases the VSG switching rate for ~ 250 fold. In addition, DNA breaks are found in the 70 bp
repeats in WT cells. Therefore, 70 bp repeat integrity is expected to significantly affect VSG switching
frequency. However, it is unknown whether any proteins specifically associate with the 70 bp repeats,
even though their sequences are highly conserved, and their associated proteins are expected to help
maintain their integrity and to participate in the regulation of VSG switching. In this small project, we aim
to use an improved “end-targeting proteomics of isolated chromatin segments” (ePICh) approach to isolate the
70 bp repeat chromatin and identify proteins associated with the 70 bp repeats by mass spectrometry. We will
validate candidates identified in the 70 bp repeat ePICh and initiate their functional analysis. Our work will
reveal clearly whether any proteins specifically associate with the 70 bp repeats, which will allow us to
investigate how 70 bp repeats integrity is maintained. Our findings will open up new avenues for better
understanding of the T. brucei pathogenesis and contribute to eradicate this parasite eventually.
项目概要
布氏锥虫会引起人类非洲锥虫病,如果不治疗,这种病通常会致命。
治疗这种疾病的药物很少,大多数都有严重的副作用并且很难治愈。
布氏锥虫感染也呈上升趋势。
非洲动物锥虫病已成为撒哈拉以南非洲地区的重大经济负担。
因此,进一步研究布氏锥虫的发病机制并确定未来发展的更好目标非常重要
抗寄生虫剂。布氏锥虫定期改变其主要表面抗原 VSG,以逃避其哺乳动物宿主。
VSG 转换是 T. brucei 的主要发病机制。
然而,VSG 转换是如何在 T 中自然启动的。
brucei 仍不清楚 T. brucei 有超过 2,500 个 VSG 基因和假基因,所有这些基因都位于
然而,VSG 仅由亚端粒多顺反子 VSG 表达表达。
VSG 是所有 ES 中的最后一个基因,距离 T. brucei 重复序列 2 kb 以内。
ES 具有非常相似的序列,但任何时候只有一个 ES 完全活跃,从而导致单一类型的 VSG
DNA 重组已被证明是 VSG 的主要途径。
大多数 VSG 基因两侧都有两个共同序列,这为转换提供了序列同源性。
DNA重组介导的VSG转换中活性和沉默VSG基因之间的重组
首先,所有 VSG 3'UTR 都有一个共同的 14 nt 序列。
其次,大多数 VSG 的上游。
ES 中的 70 bp 重复序列可以有几 kb 到几十 kb 长。
结果表明,在紧邻活性物质上游的 70 bp 重复序列中引入 DNA 双链断裂
VSG 基因将 VSG 转换率提高约 250 倍。此外,在 70 bp 处发现 DNA 断裂。
因此,70 bp 重复完整性预计会显着影响 VSG 转换。
然而,尚不清楚是否有任何蛋白质与 70 bp 重复序列特异性相关。
尽管它们的序列高度保守,并且它们的相关蛋白预计会有所帮助
在这个小项目中,我们的目标是保持其完整性并参与 VSG 切换的监管。
使用改进的“分离染色质片段的末端靶向蛋白质组学”(ePICh)方法来分离
70 bp 重复染色质并通过质谱鉴定与 70 bp 重复相关的蛋白质。
验证 70 bp 重复 ePICh 中确定的候选者并启动其功能分析。
清楚地揭示是否有任何蛋白质与 70 bp 重复序列特异性相关,这将使我们能够
研究如何保持 70 bp 重复序列的完整性,我们的研究结果将为更好地实现这一目标开辟新途径。
了解布氏锥虫的发病机制并有助于最终根除这种寄生虫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bibo Li其他文献
Bibo Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bibo Li', 18)}}的其他基金
Telomere end processing and telomere stability maintenance in trypanosomes
锥虫的端粒末端加工和端粒稳定性维持
- 批准号:
10503111 - 财政年份:2022
- 资助金额:
$ 7.43万 - 项目类别:
Mechanisms of how Trypanosoma brucei TRF maintains telomere integrity
布氏锥虫 TRF 维持端粒完整性的机制
- 批准号:
10526882 - 财政年份:2022
- 资助金额:
$ 7.43万 - 项目类别:
Telomere end processing and telomere stability maintenance in trypanosomes
锥虫的端粒末端加工和端粒稳定性维持
- 批准号:
10677878 - 财政年份:2022
- 资助金额:
$ 7.43万 - 项目类别:
Mechanisms of how Trypanosoma brucei TRF maintains telomere integrity
布氏锥虫 TRF 维持端粒完整性的机制
- 批准号:
10622535 - 财政年份:2022
- 资助金额:
$ 7.43万 - 项目类别:
Identify 70 bp repeat-associated chromatin components by End-targeting Proteomics of Isolated Chromatin segments (PICh) and initiate their functional characterization
通过分离染色质片段 (PICh) 的末端靶向蛋白质组学鉴定 70 bp 重复相关染色质成分,并启动其功能表征
- 批准号:
10293165 - 财政年份:2021
- 资助金额:
$ 7.43万 - 项目类别:
Characterize functions of T. brucei RAP1 and TRF in antigenic variation and telom
表征 T. brucei RAP1 和 TRF 在抗原变异和端粒中的功能
- 批准号:
8603220 - 财政年份:2007
- 资助金额:
$ 7.43万 - 项目类别:
Characterize functions of T. brucei RAP1 and TRF in antigenic variation and telom
表征 T. brucei RAP1 和 TRF 在抗原变异和端粒中的功能
- 批准号:
8107285 - 财政年份:2007
- 资助金额:
$ 7.43万 - 项目类别:
Characterize functions of T. brucei RAP1 and TRF in antigenic variation and telom
表征 T. brucei RAP1 和 TRF 在抗原变异和端粒中的功能
- 批准号:
8789346 - 财政年份:2007
- 资助金额:
$ 7.43万 - 项目类别:
Characterize functions of T. brucei RAP1 and TRF in antigenic variation and telom
表征 T. brucei RAP1 和 TRF 在抗原变异和端粒中的功能
- 批准号:
8414432 - 财政年份:2007
- 资助金额:
$ 7.43万 - 项目类别:
相似海外基金
The mechanism of CELF1 upregulation and its role in the pathogenesis of Myotonic Dystrophy Type 1
CELF1上调机制及其在强直性肌营养不良1型发病机制中的作用
- 批准号:
10752274 - 财政年份:2024
- 资助金额:
$ 7.43万 - 项目类别:
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.
SELENOF 是一种新型肿瘤抑制剂,也是克服乳腺癌种族差异的新靶点。
- 批准号:
10735662 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease
CRISPR-Cas 编辑作为常染色体显性多囊肾病的基因治疗
- 批准号:
10822502 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
IL-17A mRNA 靶向寡核苷酸治疗特发性肺纤维化 (IPF)
- 批准号:
10761365 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
miR-342, a novel glucocorticoid-responsive miRNA necessary for Foxp3+ regulatory T cell function
miR-342,一种新的糖皮质激素反应性 miRNA,是 Foxp3 调节 T 细胞功能所必需的
- 批准号:
10671943 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别: